Some people should not use psychedelics, and no amount of good intention, preparation, or "right mindset" changes that. Psychedelic contraindications are the specific health conditions, medications, and circumstances where the risk of harm is high enough that the responsible answer is not "later" or "carefully" but "no." This article explains the main contraindications, what the evidence actually says, and how to think about your own situation before you ever get near a decision. It is education, not medical advice.
If you are weighing an experience, treat this as the first filter, not the last word. The safest version of this conversation includes a licensed clinician who knows your full history.
If you are weighing an experience, treat this as the first filter, not the last word. The safest version of this conversation includes a licensed clinician who knows your full history.
Key takeaways
- A contraindication is a reason not to proceed. Some are absolute (a hard stop), others are relative (proceed only with professional medical oversight, which coaching does not provide).
- The most serious psychiatric flags are a personal or family history of psychosis, schizophrenia, or bipolar disorder, because of the risk of triggering mania or psychotic episodes.
- Several common medications are dangerous with psychedelics. Lithium stands out: online reports link it to a high rate of seizures. MAOI-containing brews like ayahuasca combined with certain antidepressants raise the risk of serotonin syndrome.
- Cardiovascular conditions matter because classic psychedelics raise heart rate and blood pressure, and some compounds carry specific cardiac risks.
- Pregnancy, and using psychedelics as a substitute for needed acute care, are situations where the honest answer is that safety is unknown or the risk is unjustified.
- Screening is not a formality. It exists to keep the wrong experience from happening to the wrong person at the wrong time.
What "contraindication" actually means
A contraindication is a factor that makes a given action inadvisable because the expected harm outweighs the expected benefit. Clinicians split them into two kinds.
An absolute contraindication is a hard stop. The risk is serious enough that the action should not happen regardless of framing or setting.
A relative contraindication means the risk is real but might be managed under proper medical supervision, with monitoring, adjusted timing, or medication changes handled by a prescriber. This is a clinical judgment, not a coaching one. A harm-reduction educator or coach cannot clear a relative contraindication for you, and neither can a retreat facilitator. Only a licensed medical professional who can see your records can do that.
Two more distinctions matter. Clinical-trial settings screen participants heavily, provide medical monitoring, and use pharmaceutical-grade compounds at known doses. Non-clinical settings (retreats, ceremonies, unsupervised use) have none of those safeguards, so trial safety data does not transfer to them. And "no reported cases" is not the same as "proven safe." Absence of evidence often just means the study was never done.
An absolute contraindication is a hard stop. The risk is serious enough that the action should not happen regardless of framing or setting.
A relative contraindication means the risk is real but might be managed under proper medical supervision, with monitoring, adjusted timing, or medication changes handled by a prescriber. This is a clinical judgment, not a coaching one. A harm-reduction educator or coach cannot clear a relative contraindication for you, and neither can a retreat facilitator. Only a licensed medical professional who can see your records can do that.
Two more distinctions matter. Clinical-trial settings screen participants heavily, provide medical monitoring, and use pharmaceutical-grade compounds at known doses. Non-clinical settings (retreats, ceremonies, unsupervised use) have none of those safeguards, so trial safety data does not transfer to them. And "no reported cases" is not the same as "proven safe." Absence of evidence often just means the study was never done.
Psychiatric history: psychosis, schizophrenia, and bipolar disorder
This is the category clinicians take most seriously, and it is why nearly every psychedelic trial excludes people with a personal or family history of psychotic or bipolar disorders.
A 2024 overview of reviews, systematic review, and meta-analysis in Molecular Psychiatry examined the link between psychedelics and psychosis. The authors found that the strongest risk signal sits with people who have a personal or family history of psychotic disorders, while cautioning that much of the underlying data is low quality and cannot establish causation. The practical takeaway from the research community is consistent: a known vulnerability to psychosis is treated as a serious contraindication.
Bipolar disorder deserves its own line. The core concern is that a psychedelic can tip a susceptible person into mania or a mixed state, and a 2026 systematic review and meta-analysis in Molecular Psychiatry (Eskinazi and colleagues) catalogued cases of psychedelic-induced hypomania and mania, concentrated in people with bipolar vulnerability. The naturalistic survey evidence is more mixed than you might expect: a 2025 cross-sectional study in Psychedelic Medicine (Dourron and colleagues) of people with a personal or family history of psychotic or bipolar disorders did not find that psychedelic use increased psychotic symptoms overall, and even reported fewer auditory hallucinations in some. That is limited reassurance, not a green light: a cross-sectional self-report cannot capture an acute manic episode, and it carries recall and selection bias. Given documented manic reactions and how high the stakes are, a bipolar history is still treated as a serious reason for caution and direct psychiatric involvement.
If psychosis, schizophrenia, schizoaffective disorder, or bipolar disorder is in your personal or immediate-family history, this is not a "prepare more carefully" situation. It is a "do not proceed without direct psychiatric involvement" situation.
A 2024 overview of reviews, systematic review, and meta-analysis in Molecular Psychiatry examined the link between psychedelics and psychosis. The authors found that the strongest risk signal sits with people who have a personal or family history of psychotic disorders, while cautioning that much of the underlying data is low quality and cannot establish causation. The practical takeaway from the research community is consistent: a known vulnerability to psychosis is treated as a serious contraindication.
Bipolar disorder deserves its own line. The core concern is that a psychedelic can tip a susceptible person into mania or a mixed state, and a 2026 systematic review and meta-analysis in Molecular Psychiatry (Eskinazi and colleagues) catalogued cases of psychedelic-induced hypomania and mania, concentrated in people with bipolar vulnerability. The naturalistic survey evidence is more mixed than you might expect: a 2025 cross-sectional study in Psychedelic Medicine (Dourron and colleagues) of people with a personal or family history of psychotic or bipolar disorders did not find that psychedelic use increased psychotic symptoms overall, and even reported fewer auditory hallucinations in some. That is limited reassurance, not a green light: a cross-sectional self-report cannot capture an acute manic episode, and it carries recall and selection bias. Given documented manic reactions and how high the stakes are, a bipolar history is still treated as a serious reason for caution and direct psychiatric involvement.
If psychosis, schizophrenia, schizoaffective disorder, or bipolar disorder is in your personal or immediate-family history, this is not a "prepare more carefully" situation. It is a "do not proceed without direct psychiatric involvement" situation.
Medication interactions
Some of the clearest danger comes not from the psychedelic alone but from what it collides with.
Lithium is the standout. A 2021 analysis in Pharmacopsychiatry by Nayak and colleagues reviewed online experience reports and found that of 62 reports combining lithium with a classic psychedelic, 47% described seizures, with more still describing "bad trips." By contrast, none of the 34 lamotrigine reports involved seizures. This is not a controlled trial, and self-reported forum data has obvious limits, but a signal that strong around seizures is a serious warning. Combining lithium with a classic psychedelic is widely treated as a hard stop.
MAOI-containing preparations are the other big one. Ayahuasca contains monoamine oxidase inhibitors. Taken alongside serotonergic antidepressants (SSRIs, SNRIs, or tricyclics) or other serotonergic drugs, this combination can raise the risk of serotonin syndrome, a potentially life-threatening reaction involving agitation, high fever, muscle rigidity, and cardiovascular instability. Case reports describe serotonin syndrome after ayahuasca in people on SSRIs. MAOIs also interact dangerously with a long list of foods and medications.
Tapering an antidepressant to "make room" for a psychedelic is itself a medical act with its own risks, including discontinuation effects and relapse of the underlying condition. It is not a do-it-yourself project. Any medication change belongs with the prescriber who started it.
Lithium is the standout. A 2021 analysis in Pharmacopsychiatry by Nayak and colleagues reviewed online experience reports and found that of 62 reports combining lithium with a classic psychedelic, 47% described seizures, with more still describing "bad trips." By contrast, none of the 34 lamotrigine reports involved seizures. This is not a controlled trial, and self-reported forum data has obvious limits, but a signal that strong around seizures is a serious warning. Combining lithium with a classic psychedelic is widely treated as a hard stop.
MAOI-containing preparations are the other big one. Ayahuasca contains monoamine oxidase inhibitors. Taken alongside serotonergic antidepressants (SSRIs, SNRIs, or tricyclics) or other serotonergic drugs, this combination can raise the risk of serotonin syndrome, a potentially life-threatening reaction involving agitation, high fever, muscle rigidity, and cardiovascular instability. Case reports describe serotonin syndrome after ayahuasca in people on SSRIs. MAOIs also interact dangerously with a long list of foods and medications.
Tapering an antidepressant to "make room" for a psychedelic is itself a medical act with its own risks, including discontinuation effects and relapse of the underlying condition. It is not a do-it-yourself project. Any medication change belongs with the prescriber who started it.
Cardiovascular conditions
Classic psychedelics are serotonergic and typically raise heart rate and blood pressure during the acute experience. For someone with uncontrolled hypertension, significant heart disease, or a history of dangerous arrhythmia, that ordinary physiological effect is a meaningful risk. No clinical trials have established the safety of classic psychedelics in people with pre-existing cardiovascular disease, so caution here is about unknowns as much as knowns.
There is also a longer-term theoretical concern. Classic psychedelics and MDMA act on the 5-HT2B receptor, the same receptor implicated in the valvular heart disease seen historically with certain diet drugs. A 2023 review in Expert Opinion on Drug Safety by Tagen and colleagues concluded that single or occasional doses are unlikely to pose this specific valve risk, but that repeated or chronic exposure (for example, frequent microdosing) is where the theoretical concern concentrates. No confirmed cases of psychedelic-induced valve disease have been reported, though trials have not included the heart imaging that would detect it. Separately, ibogaine carries a distinct and well-documented risk of QT prolongation and sudden cardiac death, and belongs in a different, higher-risk category entirely.
There is also a longer-term theoretical concern. Classic psychedelics and MDMA act on the 5-HT2B receptor, the same receptor implicated in the valvular heart disease seen historically with certain diet drugs. A 2023 review in Expert Opinion on Drug Safety by Tagen and colleagues concluded that single or occasional doses are unlikely to pose this specific valve risk, but that repeated or chronic exposure (for example, frequent microdosing) is where the theoretical concern concentrates. No confirmed cases of psychedelic-induced valve disease have been reported, though trials have not included the heart imaging that would detect it. Separately, ibogaine carries a distinct and well-documented risk of QT prolongation and sudden cardiac death, and belongs in a different, higher-risk category entirely.
Pregnancy, HPPD risk, and other situations
For pregnancy and breastfeeding, the honest answer is that there is very little data and controlled trials will not ethically be done. A 2026 scoping review on psychedelic exposure in pregnancy underlined how thin the evidence base is. "Unknown" is not "safe," and unknown risk to a developing fetus is a reason not to proceed.
Hallucinogen persisting perception disorder (HPPD), a condition of lasting visual disturbances after psychedelic use, is uncommon, but prevalence estimates vary widely across the literature and it can, rarely, follow even a single exposure. A prior history of HPPD or significant perceptual disturbance is a reason for caution.
Other reasons to wait include acute crisis where what is actually needed is timely clinical care, and any situation where a person cannot give genuine informed consent. These are timing and safety judgments, not moral ones.
Hallucinogen persisting perception disorder (HPPD), a condition of lasting visual disturbances after psychedelic use, is uncommon, but prevalence estimates vary widely across the literature and it can, rarely, follow even a single exposure. A prior history of HPPD or significant perceptual disturbance is a reason for caution.
Other reasons to wait include acute crisis where what is actually needed is timely clinical care, and any situation where a person cannot give genuine informed consent. These are timing and safety judgments, not moral ones.
Myth versus evidence
- "A calm mindset cancels out medical risk." Set and setting shape the psychological experience, not drug interactions, cardiac load, or seizure risk. Biology sets the baseline.
- "Natural plant medicines are safe for everyone." Ayahuasca contains MAOIs with serious drug and food interactions. "Natural" says nothing about safety.
- "Trials show psychedelics are safe, so retreats are too." Trials screen out high-risk people and provide medical monitoring. That safety profile does not transfer to unsupervised settings.
- "Family history only matters if I have symptoms myself." A family history of psychosis or bipolar disorder is itself treated as a risk factor in research and screening.
- "Microdosing is too small to matter medically." The main theoretical 5-HT2B valve concern is specifically about repeated, chronic exposure, which is what microdosing regimens involve.
A non-clinical self-screening filter
This is a reflection tool, not a clearance process. If any item is true for you, treat it as a reason to stop and talk to a licensed clinician before going further.
- Do you, or does a close biological relative, have a history of psychosis, schizophrenia, schizoaffective disorder, or bipolar disorder?
- Do you take lithium, an MAOI, or a serotonergic antidepressant (SSRI, SNRI, tricyclic)?
- Do you have a heart condition, uncontrolled high blood pressure, or a history of arrhythmia?
- Are you pregnant, trying to conceive, or breastfeeding?
- Have you had HPPD or lasting perceptual changes after past use?
- Are you currently in acute crisis, or would this be an attempt to escape rather than to integrate?
- Is there any reason you could not give full, unpressured, informed consent?
Risks, boundaries, and when to seek professional care
The boundary here is firm and worth stating plainly. Deciding whether a relative contraindication can be safely managed, adjusting or tapering psychiatric medication, and assessing cardiac fitness are all medical acts. A coach, a harm-reduction educator, and a retreat facilitator are none of them qualified to make those calls. I do not provide substances, diagnose, prescribe, or clear anyone medically, and neither should anyone else operating outside a clinical license.
If you have a psychiatric or cardiac history, or take any of the medications above, the right next step is a conversation with a doctor or psychiatrist who can see your records. If you or someone nearby is in acute danger, in the middle of a mental health emergency, or showing signs of serotonin syndrome (high fever, severe agitation, muscle rigidity, confusion), that is an emergency: contact your local official emergency services immediately. Laws and available services differ across Europe and change over time, so use the official channels in your own country.
If you have a psychiatric or cardiac history, or take any of the medications above, the right next step is a conversation with a doctor or psychiatrist who can see your records. If you or someone nearby is in acute danger, in the middle of a mental health emergency, or showing signs of serotonin syndrome (high fever, severe agitation, muscle rigidity, confusion), that is an emergency: contact your local official emergency services immediately. Laws and available services differ across Europe and change over time, so use the official channels in your own country.
Frequently asked questions
Can careful preparation cancel out a medical contraindication?
No. Preparation improves the psychological side of an experience. It does not change how a drug interacts with lithium, how your heart responds to a blood pressure spike, or how a latent vulnerability to psychosis might surface. Those risks are biological, and mindset does not overwrite them.
My relative has bipolar disorder but I have never had symptoms. Does that count?
It is treated as a risk factor. A family history of bipolar or psychotic disorders is part of why trials screen these out, and clinicians read it as a marker of vulnerability to mania or psychosis. It is a reason to involve a clinician, not to quietly proceed.
I am on an SSRI. Can I just stop it before a session?
Stopping or tapering an antidepressant is a medical decision with its own risks, including discontinuation symptoms and relapse. It is not something to manage alone or on a facilitator's advice. If a medication change is ever appropriate, only the prescriber who started it should guide it.
Is ibogaine treated the same as psilocybin or LSD?
No. Ibogaine carries a distinct and documented cardiac risk (QT prolongation and sudden death) that puts it in a separate, higher-risk category. General statements about classic psychedelics do not apply to it.
Are these contraindications the same everywhere?
The medical logic is consistent, but legal status is not. Psychedelics are controlled substances in most of Europe, and the law varies by country and changes over time. Nothing here is legal advice or encouragement to break the law.
No. Preparation improves the psychological side of an experience. It does not change how a drug interacts with lithium, how your heart responds to a blood pressure spike, or how a latent vulnerability to psychosis might surface. Those risks are biological, and mindset does not overwrite them.
My relative has bipolar disorder but I have never had symptoms. Does that count?
It is treated as a risk factor. A family history of bipolar or psychotic disorders is part of why trials screen these out, and clinicians read it as a marker of vulnerability to mania or psychosis. It is a reason to involve a clinician, not to quietly proceed.
I am on an SSRI. Can I just stop it before a session?
Stopping or tapering an antidepressant is a medical decision with its own risks, including discontinuation symptoms and relapse. It is not something to manage alone or on a facilitator's advice. If a medication change is ever appropriate, only the prescriber who started it should guide it.
Is ibogaine treated the same as psilocybin or LSD?
No. Ibogaine carries a distinct and documented cardiac risk (QT prolongation and sudden death) that puts it in a separate, higher-risk category. General statements about classic psychedelics do not apply to it.
Are these contraindications the same everywhere?
The medical logic is consistent, but legal status is not. Psychedelics are controlled substances in most of Europe, and the law varies by country and changes over time. Nothing here is legal advice or encouragement to break the law.
Where to start instead
If you are working out whether an experience is even appropriate for your situation, start with screening, not scheduling. You can take the free, confidential safety self-assessment at entheogen.expert/safety to think through your own risk factors first. It is educational and does not replace a conversation with your doctor.
You can read more about how I approach this work on my author page, and about non-clinical integration and preparation support on the services page.
You can read more about how I approach this work on my author page, and about non-clinical integration and preparation support on the services page.
Author and reviewer
Written and reviewed for scope by Vladislav Andreev, Certified Psychedelic Coach (Psychedelic Coaching Institute) and harm-reduction educator based in Barcelona. This is a coaching and education perspective, not a clinical one. I do not provide substances or medical advice.
References
- "Reconsidering evidence for psychedelic-induced psychosis: an overview of reviews, a systematic review, and meta-analysis of human studies." Molecular Psychiatry, 2024.
- Dourron et al. "Naturalistic Psychedelic Use and Psychotic Symptoms." Psychedelic Medicine, 2025.
- Nayak SM, et al. "Classic Psychedelic Coadministration with Lithium, but Not Lamotrigine, is Associated with Seizures." Pharmacopsychiatry, 2021. DOI: 10.1055/a-1524-2794.
- Tagen M, et al. "Serotonin 5-HT2B receptor agonism and valvular heart disease." Expert Opinion on Drug Safety, 2023. DOI: 10.1080/14740338.2023.2248883.
- "Medical Complications of Psychedelics." Primary Care Companion for CNS Disorders.
- Martinotti G, et al. "Hallucinogen Persisting Perception Disorder." Brain Sciences, 2018.
- Albert OM, Arthur A. "Psychedelic exposure in pregnancy: a scoping review." 2026. DOI: 10.1177/20420986261436104.
- Eskinazi M, Nasserdine R, Cusin RM, et al. "Psychedelic-induced hypomania and mania: a systematic review and meta-analysis." Molecular Psychiatry, 2026. DOI: 10.1038/s41380-026-03657-6.
Educational content only. This is not medical advice, therapy, or a clinical diagnosis, and it does not encourage illegal activity. It exists to reduce risk for adults making their own decisions. Reviewed for scope by Vladislav Andreev, Certified Psychedelic Coach (Psychedelic Coaching Institute), harm-reduction educator, Barcelona.